Spots Global Cancer Trial Database for Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression
Official Title: Phase II, Single-arm Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression
Study ID: NCT03052478
Conditions
Interventions
Study Description
Brief Summary: There is no accepted standard therapy for patients with advanced gastric cancer who have progressed during or after second-line therapy. The role of 3rd line treatment in advanced gastric cancer has not been proven. As a novel target of gastric cancer, SMO overexpression is chosen in this study, and the investigators plan this study to evaluate the efficacy and safety of vismodegib in gastric cancer. The doses of vismodegib are based on trials of basal cell carcinoma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Samsung Medical Center, Seoul City, Seoul, Korea, Republic of
Contact Details
Name: Jeeyun Lee, MD, PhD
Affiliation: Division of Hematology-Oncology, SMC
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
